Salisbury, UK, 16th October 2012: NanoSight, leading manufacturers of unique nanoparticle characterization technology, reports on the characterization of nanoparticles at the NanoLab of the Norwegian University of Science & Technology, NTNU.
NTNU NanoLab is a cross faculty, strategic initiative with the objective to coordinate and promote nanoscience and nanotechnology at NTNU. The laboratories are well-equipped with state of the art instrumentation designed to be used by as many researchers from as many disciplines as possible.
For example, Katarzyna Psonka-Antonczyk is a post-doctoral fellow in the Biophysics and Medical Technology group within the Department of Physics. Her interests include the characterization of nanovesicles (exosomes) with sizes ranging from 30 to a few hundred nanometers secreted by cancer cells to the extracellular matrix. Exosomes are intercellular shuttle vehicles of various materials and contain information that can reprogram targeted cells. Exosomes contain membrane proteins, cytosolic proteins and small RNAs (miRNA). These vesicles are transported by bodily fluids (blood) and can likely fuse back with plasma membranes, introducing new proteins and RNA in new cells distant from the cell of origin. She is applying single-molecule techniques like atomic force microscopy and total internal reflection fluorescence microscopy to visualize individual exosomes and to characterize their membrane repertoire.
Knowing the concentration of secreted exosomes can facilitate estimation of the secretory abilities of cells and can help in further sample preparation. When coupled with fluorescent light, the NanoSight Nanoparticle Tracking Analysis system enables the analysis of exosome samples to provide information of various distinct subpopulations of vesicles by labeling with specific antibodies tagged with a fluorescent reporter. In the opinion of Dr Psonka-Antonczyk, the NanoSight LM10 has proven to be a very suitable instrument to access the concentration and size profile of exosomes.
Prior to using NanoSight, Dr Psonka-Antonczyk tried to employ dynamic light scattering but the results were rather irreproducible and not very reliable. In contrast, NanoSight exceeded her expectations. She said “NanoSight’s system is simple and easy to operate in providing information on the exosomes concentration and size profile in a very short time. I can also use it as a test measurement providing the first glance on the exosomes before running more elaborate and time-consuming experiments.”
The range of applications for NTA at NanoLab is diverse. For example, metallic and magnetic nanoparticles (Chemical Engineering) used for biomedical applications including targeted drug delivery and MRI contrast enhancement are studied by Dr Gurvinder Singh. He likes the NTA approach because “it provides the determination of particle concentration, better resolution of particle size and size distribution with real time visualization. This instrument is more impressive than DLS.”
The open approach of NanoLab to encourage users from across the different faculties is illustrated in the way NTNU users may even book time online: http://www.norfab.no/technologies/characterization/ntnu-nanolab/nanosight/.
To find out about the company and to learn more about particle characterization using NanoSight’s unique Nanoparticle Tracking Analysis solutions, visit www.nanosight.com and register to receive the next issue of NanoTrail, the company’s electronic newsletter.
About NanoSight:
NanoSight delivers the world’s most versatile and proven multi-parameter nanoparticle analysis in a single instrument.
NanoSight’s “Nanoparticle Tracking Analysis” (NTA) detects and visualizes populations of nanoparticles in liquids down to 10 nm, dependent on material, and measures the size of each particle from direct observations of diffusion. Additionally, NanoSight measures concentration and a fluorescence mode differentiates suitably-labelled particles within complex background suspensions. Zeta potential measurements are similarly particle-specific. It is this particle-by-particle methodology that takes NTA beyond traditional light scattering and other ensemble techniques in providing high-resolution particle size distributions and validates data with information-rich video files of the particles moving under Brownian motion.
This simultaneous multiparameter characterization matches the demands of complex biological systems, hence its wide application in development of drug delivery systems, of viral vaccines, and in nanotoxicology. This real-time data gives insight into the kinetics of protein aggregation and other time-dependent phenomena in a qualitative and quantitative manner. NanoSight has a growing role in biodiagnostics, being proven in detection and speciation of nanovesicles (exosomes) and microvesicles.
NanoSight has installed approaching 500 systems worldwide with users including BASF, GlaxoSmithKline, Merck, Novartis, Pfizer, Proctor and Gamble, Roche and Unilever together with the most eminent universities and research institutes. NanoSight’s technology is validated by 450+ third party papers citing NanoSight results and by the ASTM Standard E2834, consolidating NanoSight’s leadership position in nanoparticle characterization. For more information, visit www.nanosight.com
For further information:
Please contact NanoSight direct or their marketing agency, Talking Science:
NanoSight Limited
Minton Park
London Road
Amesbury SP4 7RT UK
T +44(0)1980 676060
F +44(0)1980 624703
www.nanosight.com
jeremy.warren@nanosight.com
Talking Science Limited
39 de Bohun Court
Saffron Walden
Essex CB10 2BA UK
T +44(0)1799 521881
M +44(0)7843 012997
www.talking-science.com
jezz@talking-science.com
